With their low immunogenicity and excellent deliverability,
extracellular
vesicles (EVs) are promising platforms for drug delivery systems.
In this study, hydrophobic molecule loading techniques were developed
via an exchange reaction based on supramolecular chemistry without
using organic solvents that can induce EV disruption and harmful side
effects. To demonstrate the availability of an exchanging reaction
to prepare drug-loading EVs, hydrophobic boron cluster carborane (CB)
was introduced to EVs (CB@EVs), which is expected as a boron agent
for boron neutron capture therapy (BNCT). The exchange reaction enabled
the encapsulation of CB to EVs without disrupting their structure
and forming aggregates. Single-particle analysis revealed that an
exchanging reaction can uniformly introduce cargo molecules to EVs,
which is advantageous in formulating pharmaceuticals. The performance
of CB@EVs as boron agents for BNCT was demonstrated in vitro and in
vivo. Compared to L-BPA, a clinically available boron agent, and CB
delivered with liposomes, CB@EV systems exhibited the highest BNCT
activity in vitro due to their excellent deliverability of cargo molecules
via an endocytosis-independent pathway. The system can deeply penetrate
3D cultured spheroids even in the presence of extracellular matrices.
The EV-based system could efficiently accumulate in tumor tissues
in tumor xenograft model mice with high selectivity, mainly via the
enhanced permeation and retention effect, and the deliverability of
cargo molecules to tumor tissues in vivo enhanced the therapeutic
benefits of BNCT compared to the L-BPA/fructose complex. All of the
features of EVs are also advantageous in establishing anticancer agent
delivery platforms.